Design future-proofed, broadly neutralizing antibodies that can get ahead of the evolution of resistance.
Therapeutic antibodies can be used to treat viral infections by targeting specific antigens, blocking their activity, and invoking an immune response.
As viruses mutate, they develop resistance to antibodies, rendering therapeutics ineffective. This problem of treating viral infection is one of understanding the evolvability of a virus. Despite widespread research, current discovery tools have limited success in countering viral resistance.
Using our ability to understand the constraints on viral evolution, Evozyne is developing an approach to generate future-proofed, broadly neutralizing antibodies. Our first application of this platform is a variant-resistant COVID-19 antibody.